Lynx1 Capital Management LP T Scan Therapeutics, Inc. Transaction History
Lynx1 Capital Management LP
- $270 Million
- Q1 2025
A detailed history of Lynx1 Capital Management LP transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 5,357,347 shares of TCRX stock, worth $9.16 Million. This represents 2.73% of its overall portfolio holdings.
Number of Shares
5,357,347
Previous 5,357,347
-0.0%
Holding current value
$9.16 Million
Previous $16.2 Million
54.3%
% of portfolio
2.73%
Previous 6.28%
Shares
4 transactions
Others Institutions Holding TCRX
# of Institutions
92Shares Held
39.8MCall Options Held
0Put Options Held
0-
Bvf Inc San Francisco, CA4.89MShares$8.36 Million0.3% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$7.63 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.5MShares$5.99 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$4.76 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.36MShares$4.03 Million0.0% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $32.4M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...